Neurospychiatric symptoms in HIV infected patients and the role of efavirenz;Troubles neuropsychiatriques chez les patients infectés par le VIH et rôle de l'efavirenz

Medecine et Maladies Infectieuses

Volumn 34, Issue 10, 2004, Pages 435-449

  Bary, M ^a   David, F ^b   Gasnault, J ^c   Kerneis, H ^d   Linard, F ^e   Longuet, P ^f   Pelissolo, A ^g   Ravaux, I ^h  

^a Centre Croix Rouge du Moulin Joly   (France)

^b CENTRE HOSPITALIER   (France)

^c BICÊTRE HOSPITAL   (France)

^d Service du Dr M Windisch   (France)

^e HÔPITAL TENON   (France)

^f BICHAT HOSPITAL   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Efavirenz; Effets ind sirables; HIV infection; Infection VIH; Side effects

Indexed keywords

ANTIVIRUS AGENT; EFAVIRENZ;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; DELIRIUM; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; EPIDEMIOLOGICAL DATA; HALLUCINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MANIA; MEMORY DISORDER; MENTAL DISEASE; NEUROPSYCHIATRY; PSYCHOSIS; REVIEW; SUICIDE ATTEMPT; SYMPTOM;

EID: 7444257913     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.medmal.2004.04.007     Document Type: Article

References (97)

1. Staszewski S., Morales-Ramirez J., Tashima K.T., Rachlis A., Skiest D., Stanford J., et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 341:(25):1999;1865-1873. Study 006 Team
2. Albrecht M.A., Bosch R.J., Hammer S.M., Liou S.H., Kessler H., Para M.F., et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 345:(6):2001;398-407
3. Vray M., Meynard J.L., Dalban C., Morand-Joubert L., Brun-Vezinet F., Clavel F., et al. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther. 8:(5):2003;427-434
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth edition:2000;APA Press, Washington DC. Texte Revision (DSM-IV-TR)
5. Gutierrez R., Atkinson J.H., Grant I. Mild neurocognitive disorder: needed addition to the nosology of cognitive impairment (organic mental) disorders. J Neuropsychiatry Clin Neurosci. 5:(2):1993;161-177
6. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Neurology. 47:(5):1996;1247-1253
7. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology. 41:(6):1991;778-785
8. Lépine J.P., Chignon J.M. Sémiologie des troubles anxieux et phobiques. Encycl. Méd. Chir. Psychiatrie 37-112-A-10. Paris. 1994;1-13
9. Pelissolo A. Dépister et diagnostiquer l'anxiété Rev Prat. 14:(NS):1999;5-10
10. Tribolet S., Shahidi M. Précis de sémiologie des troubles psychiques: heures de France. 2000
11. Verdoux H., Demotes-Mainard C.H., d'Elbée R., Bourgeois M. Sémiologie des états d'excitation. 1998;Elsevier, Paris
12. Guelfi J.D. Psychiatrie. 1999;PUF, Paris
13. Small G.W. What we need to know about age related memory loss. BMJ. 324:(7352):2002;1502-1505
14. Selnes O.A., McArthur J.C., Royal W., Updike M.L., Nance-Sproson T., Concha M., et al. HIV-1 infection and intravenous drug use: longitudinal neuropsychological evaluation of asymptomatic subjects. Neurology. 42:(10):1992;1924-1930
15. Starace F., Bartoli L., Aloisi M.S., Antinori A., Narciso P., Ippolito G., et al. Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Acta Psychiatr Scand. 106:(1):2002;20-26
16. Lochet P., Peyriere H., Lotthe A., Mauboussin J.M., Delmas B., Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 4:(1):2003;62-66
17. Sacktor N., McDermott M.P., Marder K., Schifitto G., Selnes O.A., McArthur J.C., et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 8:(2):2002;136-142
18. Sacktor N.C., Lyles R.H., Skolasky R.L., Anderson D.E., McArthur J.C., McFarlane G., et al. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Neurology. 52:(8):1999;1640-1647. Multicenter AIDS Cohort Study (MACS)
19. von Giesen H.J., Koller H., Theisen A., Arendt G. Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients. J Acquir Immune Defic Syndr. 29:(4):2002;363-367
20. Deutsch R., Ellis R.J., McCutchan J.A., Marcotte T.D., Letendre S., Grant I. AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. AIDS. 15:(14):2001;1898-1899
21. Résumé des caractéristique du produit. 2002;SUSTIVA
22. Senon J.L., Sechter D., Richard D. Mémento de thérapeutique psychiatrique. 1996;Hermann Edition Sciences et Arts, Paris
23. Sutton D.A., Moldofsky H., Badley E.M. Insomnia and health problems in Canadians. Sleep. 24:(6):2001;665-670
24. Janson C., Gislason T., De Backer W., Plaschke P., Bjornsson E., Hetta J., et al. Prevalence of sleep disturbances among young adults in three European countries. Sleep. 18:(7):1995;589-597
25. Vela-Bueno A., De Iceta M., Fernandez C. Prevalence of sleep disorders in Madrid, Spain. Gac Sanit. 13:(6):1999;441-448
26. Rubinstein M.L., Selwyn P.A. High prevalence of insomnia in an outpatient population with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 19:(3):1998;260-265
27. Halman M. Traitement de la dépression et des symptômes neuropsychiatriques associés au VIH/sida et aux antirétroviraux. Can J Infect Dis. 12:(Suppl C):2001;9C-20C
28. Fumaz C.R., Tuldra A., Ferrer M.J., Paredes R., Bonjoch A., Jou T., et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz vs protease inhibitor-containing regimens. J Acquir Immune Defic Syndr. 29:(3):2002;244-253
29. Goldenberg D., Boyle B. Psychiatric safety of efavirenz. XIII International AIDS conference, July 9-14 2000. 2000;. Durban: [abstract] WePeB4238
30. Johnson M., Staszewski S., Nelson M., Barros C., Rubio R., Morales-Ramirez J.O., et al. Low Incidence and Prevalence of CNS and Psychiatric Adverse Experiences with Long Term Use of Efavirenz. ECCATHI October 28-31 2001. 109:2001;143 Provoli Publicity, Athènes. [abstract]
31. Doherty G., Wong R., Seaton R.A., Fox R., Kennedy D., Nandwani R., et al. A retrospective analysis of neuropsychiatric side effects of efavirenz in Glasgow. 6th International Congress On Drug Therapy in HIV Infection. 62:2002;153. Glasgow: [abstract]
32. Max B., Garey K., Schwartz D., Bult J., Sherer R. Efavirenz tolerability in the real world: relation to mental illness, alcohol, and illicit drug use in a large, urban HIV clinic. XIII International AIDS Conference, July 9-14 2000. 2000;. Durban: [abstract] WePeB4288
33. Pélissolo A., Lépine J.P. Epidemiology of depression and anxiety disorders. den Boer J.A. SSRIs in depression and anxiety. 2001;1-23 John Wiley & Sons Ltd, Chichester
34. Kerrihard T., Breitbart W., Dent R., Strout D. Anxiety in patients with cancer and human immunodeficiency virus. Semin Clin Neuropsychiatry. 4:(2):1999;114-132
35. Cohen M., Hoffman R.G., Cromwell C., Schmeidler J., Ebrahim F., Carrera G., et al. The prevalence of distress in persons with human immunodeficiency virus infection. Psychosomatics. 43:(1):2002;10-15
36. Kilbourne A.M., Justice A.C., Rabeneck L., Rodriguez-Barradas M., Weissman S. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol. 54:(Suppl 1):2001;S22-S28
37. Zinkernagel C., Taffe P., Rickenbach M., Amiet R., Ledergerber B., Volkart A.C., et al. Importance of mental health assessment in HIV-infected outpatients. J Acquir Immune Defic Syndr. 28:(3):2001;240-249
38. Dew M.A., Becker J.T., Sanchez J., Caldararo R., Lopez O.L., Wess J., et al. Prevalence and predictors of depressive, anxiety and substance use disorders in HIV-infected and uninfected men: a longitudinal evaluation. Psychol Med. 27:(2):1997;395-409
39. Pelissolo A. Epidémiologie des troubles psychopathologiques lors des maladies infectieuses. Encéphale Praticien. 23:(1):1997;3-8
40. Dorfman D., Chu A., Haubrich R., Naseer M., Petersen C., Schmeidler J., et al. Neuropsychiatric Complications of Efavirenz (EFV): Results of a Randomized Prospective Comparison with Nelfinavir (NFV) in Antiretroviral (ARV)-Naïve Patients. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002. 315:2002;719 Foundation for Retrovirology and Human Health, Seattle. [abstract]
41. Blanch J., Martinez E., Rousaud A., Blanco J.L., Garcia-Viejo M.A., Peri J.M., et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr. 27:(4):2001;336-343
42. Rouillon F. Les troubles dépressifs: John Libbey Eurotext. 1997
43. Penzak S.R., Reddy Y.S., Grimsley S.R. Depression in patients with HIV infection. Am J Health Syst Pharm. 57:(4):2000;376-386. quiz 387-9
44. Ciesla J.A., Roberts J.E. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 158:(5):2001;725-730
45. Turrina C., Fiorazzo A., Turano A., Cacciani P., Regini C., Castelli F., et al. Depressive disorders and personality variables in HIV positive and negative intravenous drug-users. J Affect Disord. 65:(1):2001;45-53
46. Angelino A.F., Treisman G.J. Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clin Infect Dis. 33:(6):2001;847-856
47. Balderson K., Halman M., Jones K. Psychiatric aspects of HIV disease. Primary Care Psychiatry. 6:(3):2000;83-92
48. Low-Beer S., Chan K., Yip B., Wood E., Montaner J.S., O'Shaughnessy M.V., et al. Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr. 23:(4):2000;295-301
49. Judd F.K., Cockram A.M., Komiti A., Mijch A.M., Hoy J., Bell R. Depressive symptoms reduced in individuals with HIV/AIDS treated with highly active antiretroviral therapy: a longitudinal study. Aust N Z J Psychiatry. 34:(6):2000;1015-1021
50. Vignat J.P., Prieto N. Manie et épidémiologie. Psychiatrie Française. 32:(3/01):2001
51. Bing E.G., Burnam M.A., Longshore D., Fleishman J.A., Sherbourne C.D., London A.S., et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 58:(8):2001;721-728
52. Blanch J., Corbella B., Garcia F., Parellada E., Gatell J.M. Manic syndrome associated with efavirenz overdose. Clin Infect Dis. 33:(2):2001;270-271
53. Johns L.C., Nazroo J.Y., Bebbington P., Kuipers E. Occurrence of hallucinatory experiences in a community sample and ethnic variations. Br J Psychiatry. 180:2002;174-178
54. Tien A.Y. Distributions of hallucinations in the population. Soc Psychiatry Psychiatr Epidemiol. 26:(6):1991;287-292
55. Ohayon M.M. Prevalence of hallucinations and their pathological associations in the general population. Psychiatry Res. 97:(2-3):2000;153-164
56. Olfson M., Lewis-Fernandez R., Weissman M.M., Feder A., Gameroff M.J., Pilowsky D., et al. Psychotic symptoms in an urban general medicine practice. Am J Psychiatry. 159:(8):2002;1412-1419
57. Dhossche D., Ferdinand R., Van der Ende J., Hofstra M.B., Verhulst F. Diagnostic outcome of self-reported hallucinations in a community sample of adolescents. Psychol Med. 32:(4):2002;619-627
58. De Ronchi D., Faranca I., Forti P., Ravaglia G., Borderi M., Manfredi R., et al. Development of acute psychotic disorders and HIV-1 infection. Int J Psychiatry Med. 30:(2):2000;173-183
59. Alciati A., Fusi A., D'Arminio Monforte A., Coen M., Ferri A., Mellado C. New-onset delusions and hallucinations in patients infected with HIV. J Psychiatry Neurosci. 26:(3):2001;229-234
60. Harris M.J., Jeste D.V., Gleghorn A., Sewell D.D. New-onset psychosis in HIV-infected patients. J Clin Psychiatry. 52:(9):1991;369-376
61. Lempière T. Dépression et suicide. 1999;Masson, Paris
62. Bourgeois M., Facy F., Rouillon F., Verdoux H. Épidé miologie du suicide. Encycl. Méd. Chir. Psychiatrie 37-397-A-20. 1997;10 Elsevier, Paris
63. Starace F., Sherr L. Suicidal behaviours, euthanasia and AIDS. AIDS. 12:(4):1998;339-347
64. Gil F., Passik S., Rosenfeld B., Breitbart W. Psychological adjustment and suicidal ideation in patients with AIDS. AIDS Patient Care STDS. 12:(12):1998;927-930
65. Cochand P., Bovet P. HIV infection and suicide risk: an epidemiological inquiry among male homosexuals in Switzerland. Soc Psychiatry Psychiatr Epidemiol. 33:(5):1998;230-234
66. Kalichman S.C., Heckman T., Kochman A., Sikkema K., Bergholte J. Depression and thoughts of suicide among middle-aged and older persons living with HIV-AIDS. Psychiatr Serv. 51:(7):2000;903-907
67. Simoni J.M., Nero D.K., Weinberg B.A. Suicide attempts among seropositive women in New York City. Am J Psychiatry. 155:(11):1998;1631-1632
68. Vandentorren S., Mercié P., Marimoutou C., Dabis F. (GECSA). Evolution des causes de décès des patients infectés par le VIH dans la cohorte Aquitaine. BEH. 17:1999;1985-1997
69. May T., Lewden C., Bonnet F., Heripret L., Bevilacqua S., Jougla E., et al. Characteristics and Causes of Death Among HIV-infected Patients Who had a Good Immunovirologic Response under HAART: French National Survey "Mortalité 2000" 10th Conference on Retroviruses and Opportunistic Infections, February10-14, 2003:2003;913 Foundation for Retrovirology and Human Health, Boston. [abstract]
70. Grassi L., Mondardini D., Pavanati M., Sighinolfi L., Serra A., Ghinelli F. Suicide probability and psychological morbidity secondary to HIV infection: a control study of HIV-seropositive, hepatitis C virus (HCV)-seropositive and HIV/HCV-seronegative injecting drug users. J Affect Disord. 64:(2-3):2001;195- 202
71. McNaught A., Spicer J. Theoretical perspectives on suicide in gay men with AIDS. Soc Sci Med. 51:(1):2000;65-72
72. Parrish D., Godbey J. Use of efavirenz in a low income population [abstract]. XIII International AIDS Conference July 9-14 2000. 2000;. Durban: [abstract] WePe4138
73. Gill M.J., Rachlis A., Walmsley S., Halman M. Recommandations du groupe d'experts canadiens sur le traitement des symptômes du SNC liés à l'efavirenz. Can J Infect Dis. 12:(Suppl C):2001;21C-32C
74. Landovitz R, Winkelman J, Yawetz S, Koziol C, Sax P. Efavirenz increases slow-wave sleep, 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003. 314. Boston: Foundation for Retrovirology and Human Health; 2003. p. 715 [abstract]
75. Benedek I.H. Evaluation of efavirenz on the pharmacokinetics of lorazepam in healthly volunteers. 39th Annual Meeting of the Infectious Diseases Society of America, September 26 - 29 1999. 1026:1999;367 Clinical Infectious Diseases, San Francisco. [abstract]
76. Pelissolo A. Les traitements anxiolytiques: évolution des pratiques et des indications. Annales de Psychiatrie. 16:2001;200-204
77. Lévy M. Les maladies de l'humeur: estem. 1998
78. o 5):1997;36-42
79. Linard F., Beau P., Silvestre D. Psychiatrie et infections à VIH chez l'adulte. Encycl. Méd. Chir. Psychiatrie 37-550-A-20. 1995;11 Elsevier, Paris
80. Ruiz N. Efavirenz plasma levels and therapeutic reponse are unaffected in patients concomitantly receiving selective serotonin reuptake inhibitors. 40th ICAAC September 17 - 20 2000. 332:2000;1635. Toronto: [abstract]
81. Ellen S.R., Judd F.K., Mijch A.M., Cockram A. Secondary mania in patients with HIV infection. Aust N Z J Psychiatry. 33:(3):1999;353-360
82. Olié J.P., Daléry J., Azorin J.M. Médicaments antispychotiques: évolution ou révolution ? 2001;Acanthe, Paris
83. Conférence de consensus. La crise suicidaire: reconnaître et prendre en charge. L'information Psychiatrique. 77:(3):2001;265-274
84. Scheer S., McQuitty M., Denning P., Hormel L., Stephens B., Katz M., et al. Undiagnosed and unreported AIDS deaths: results from the San Francisco Medical Examiner. J Acquir Immune Defic Syndr. 27:(5):2001;467-471
85. Marzolini C., Telenti A., Decosterd L.A., Greub G., Biollaz J., Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 15:(1):2001;71-75
86. Nunez M., Gonzalez De Requena D., Gallego L., Jimenez-Nacher I., Gonzalez-Lahoz J., Soriano V. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr. 28:(4):2001;399-400
87. Fiske W.D. An assessment of population pharmacokinetic parameters of efavirenz on nervous system symptoms and suppression of HIV RNA. 41st ICAAC, December 16-19 2001. 2001;1727. Chicago: [abstract]
88. Raspall T., Blanco J., Blanch J. Neuropsychological disturbances and PK levels in patients receiving efavirenz: a pilot study. 4th International Workshop on Clinical Pharmacology of HIV Therapy, 27-29 March 2003. 2003;4.7. Cannes: [Abstract]
89. Ribaudo H., Clifford D., Gulick R., Shikuma C., Klingman K., Snyder S., et al. Relationship between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response, and race: results from ACTG A5095/A5097s. 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004. 2004;132 Foundation for Retrovirology and Human Health, San Francisco. [abstract]
90. Haas D., Ribaudo H., Kim R., Tierney C., Wilkinson G., Gulick R., et al. A common CYP2B6 Variant is associated with efavirenz pharmacokinetics and central nervous system side effects: AACTG Study NWCS214. 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004. 2004;133 Foundation for Retrovirology and Human Health, San Francisco. [abstract]
91. Blanch J., Rousaud A., Martinez E., De Lazzari E., Peri J.M., Milinkovic A., et al. Impact of lipodystrophy on the quality of life of HIV-1-infected patients. J Acquir Immune Defic Syndr. 31:(4):2002;404-407
92. Pelissolo A., Lépine J.P. Epidemiology of depression and anxiety disorders. Montgomery S.A., den Boer J.A. SSRIs in depression and anxiety. 2001;1-23 John Wiley & Sons Ltd, Chichester
93. Wechsler D. Échelle d'intelligence de Wechsler pour adultes (WAIS-III). 2000;Les éditions du centre de psychologie appliquée, Paris
94. Dubois B., Touchon J., Portet F., Ousset P.J., Vellas B., Michel B. "The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease. Presse Med. 31:(36):2002;1696-1699
95. Dubois B., Slachevsky A., Litvan I., Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 55:(11):2000;1621-1626
96. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 67:(6):1983;361-370
97. Spinhoven P., Ormel J., Sloekers P.P., Kempen G.I., Speckens A.E., Van Hemert A.M. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med. 27:(2):1997;363-370